A human-derived protein SBP (HBsAg-binding protein) can bind to hepatitis B virus surface antigen (HBsAg) and enhance the immune response to hepatitis B virus (HBV) vaccine

Molecular Immunology

Volumn 53, Issue 1-2, 2013, Pages 60-71

  Zhang, Chongwen ^a,b   Gong, Li ^a   Chen, Yuanyuan ^a   Wang, Xiaohua ^a   Zhu, Sibo ^a   Li, Ding ^a   Pang, Yun ^a   Yin, Yue ^a   Liu, Xi ^a   Zhu, Naishuo ^a,c  

^a FUDAN UNIVERSITY   (China)

^b Shanghai Testing and Supervising Station on Aquatic Products Quality   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Adjuvant; Affinity; Hepatitis b virus; Vaccine

Indexed keywords

BINDING PROTEIN; GAMMA INTERFERON; HBSAG BINDING PROTEIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN G; INTERLEUKIN 2; INTERLEUKIN 4; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA LIBRARY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; ISOELECTRIC POINT; LIVER; MALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; CARRIER PROTEINS; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE LIBRARY; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PHAGOCYTOSIS; PROTEIN BINDING; PROTEIN STRUCTURE, QUATERNARY; RECEPTORS, VIRUS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

HEPATITIS B VIRUS; MUS;

EID: 84863831227     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2012.06.014     Document Type: Article

References (29)

1. Belloni C., Tinelli C., Orsolini P., et al. Revaccination against hepatitis B virus of non-responding and low-responding infants immunized at birth. A parallel evaluation of rubella and tetanus vaccine. Vaccine 1998, 16:399-402.
2. Buti M., Viladomiu L., Jardi R., et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients. American Journal of Nephrology 1992, 12:144-147.
3. Cai X., Wang J., Wang Y., et al. Expression, purification and characterization of recombinant human interleukin-22 in Pichia pastoris. Molecular Biology Reports 2010, 37(6):2609-2613.
4. Dienstag J., Perillo R., Schiff E., et al. A preliminary trial of lamivudine for chronic hepatitis B infection. New England Journal of Medicine 1995, 333:1657-1661.
5. Glenny A., Pope C., Waddington H., et al. The antigenic value of toxoid precipitated by potassium alum. Journal of Pathology and Bacteriology 1926, 29:38-45.
6. Gluck R., Metcalfe I.C. Novel approaches in the development of immuno-potentiating reconstituted influenza virosomes as efficient antigen carrier systems. Vaccine 2003, 21(7-8):611-615.
7. Goncalves L., Barboza L., Albarrán B., et al. Pattern of T cell activation in absence of protective immunity against hepatitis B virus. Review. Investigacion Clinica 2006, 47(1):83-96.
8. Gupta R.K., Relyveld E.H., Lindblad E.B., et al. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 1993, 11(3):293-306.
9. Gupta R.K., Rost B.E., Relyveld E.H., et al. Adjuvant properties of aluminum and calcium compounds. Pharmaceutical Biotechnology 1995, 6:229-248.
10. Houshmand H., Bergqvist A. Interaction of hepatitis C virus NS5A with La protein revealed by T7 phage display. Biochemical and Biophysical Research Communications 2003, 309(3):695-701.
11. Inaba K., Inaba M., Romani N., et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. Journal of Experimental Medicine 1992, 176:1693-1702.
12. Jackson R.M., Gabb H.A., Srernberg M.J.E. Rapid refinement of protein interfaces incorporating salvation: application to the docking problem. Journal of Molecular Biology 1998, 276:265-285.
13. Lai C., Chien R., Leung N., et al. A one-year trial of lamivudine for chronic hepatitis B. New England Journal of Medicine 1998, 339:61-68.
14. Lok A.S. The maze of treatments for hepatitis B. New England Journal of Medicine 2005, 352:2743-2746.
15. Miriam J.A., Rob L.L., Jerome I.T., et al. Centers for Disease Control. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recommendations and Reports 2001, 50(RR-5):1-43.
16. Nevens F., Main J., Honkoop P., et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997, 113:1258-1263.
17. Peces R., de la Torre M., Alcazar R., et al. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. American Journal of Kidney Diseases 1997, 29:239-245.
18. Podda A., Del Giudice G. MF59-adjuvanted vaccines: increased immunogenecity with an optimal safety profile. Expert Review of Vaccines 2003, 2(2):197-203.
19. Reed S.G., Bertholet S., Coler R.N., Friede M. New horizons in adjuvants for vaccine development. Trends in Immunology 2009, 30(January (1)):23-32.
20. Schwede T., Kopp J., Guex N., Peitsch M.C. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Research 2003, 31:3381-3385.
21. Shi C., Zhao S., Zhang K., et al. Preparation of colloidal gold immunochromatography strip for detection of methamidophos residue. Journal of Environmental Sciences (China) 2008, 20(11):1392-1397.
22. Sung W.K., Lu Y., Lee C.W., et al. Deregulated direct targets of the hepatitis B virus (HBV) protein, HBx, identified through chromatin immunoprecipitation and expression microarray profiling. Journal of Biological Chemistry 2009, 284(33):21941-22154.
23. Verma R., Khanna P., Prinja S., et al. Hepatitis B Vaccine in national immunization schedule: a preventive step in India. Human Vaccines 2011, 7(12):1387-1388.
24. Vildozola H. Vaccination against Hepatitis B: 20 years later. Revista de Gastroenterologia del Peru 2007, 27:57-66.
25. Wen Y.M., Liu H.J., Chen H.Z., et al. Studies on intrahepatic hepatitis B virus DNA in 98 viral hepatitis B patients. Chinese Medical Journal 1986, 99(11):861-865.
26. Wheeler A.W., Marshall J.S., Ulrich J.T. A th1-Inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. International Archives of Allergy and Immunology 2001, 126:135-139.
27. Wong D.K.H., Cheung A.M., O'Rourke K., et al. Effect of alpha-interferon in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Annals of Internal Medicine 1993, 119:312-323.
28. Wu C., Zhang X., Tian Y., et al. Biological significance of amino acid substitutions in hepatitis B surface antigen (HBsAg) for glycosylation, secretion, antigenicity and immunogenicity of HBsAg and hepatitis B virus replication. Journal of General Virology 2010, 91(Pt 2):483-492.
29. Xing Y.P., Huang Z.H., Yan L.N., et al. The ability of Hepatitis B surface antigen DNA vaccine to elicit cell-mediated immune responses, but not antibody responses, was affected by the deglysosylation of S antigen. Vaccine 2008, 26:5145-5152.